New 6,7-disubstituted-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carb oxy lic acids of the formula (I) ##STR1## in which X represents halogen or nitro and A represents ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined hereinbelow are disclosed as well as their usefulness as antibacterial agents.

The present invention relates to new 6,7-disubstituted 
1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, 
processes for their preparation and antibacterial agents and feed 
additives containing these compounds. 
It has been found that the new 6,7-disubstituted 
1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids of 
the formula (I) 
##STR3## 
in which X represents halogen or nitro and 
A represents 
##STR4## 
or halogen, in particulr chlorine or fluorine, wherein 
R.sup.1 represents hydrogen, a branched or straight-chain alkyl group with 
1 to 4 carbon atoms, which can optionally be substituted by a hydroxyl or 
methoxy group, a phenacyl radical which is optionally substituted by 
hydroxyl, methoxy, chlorine or fluorine, an oxoalkyl radical with 2 to 4 
carbon atoms, 4-aminobenzyl, formyl or acetyl, or 
represents the radical 
##STR5## 
R.sup.2 represents hydrogen or methyl, or phenyl or thienyl which is 
optionally substituted by chlorine, fluorine, methyl, hydroxyl or methoxy, 
R.sup.3 represents hydrogen or methyl and 
R.sup.4 represents hydrogen, hydroxyl, amino, alkyl- or dialkyl-amino with 
1 or 2 carbon aotms in the alkyl group, hydroxymethyl, aminomethyl or 
alkyl- or dialkyl-aminomethyl with 1 or 2 carbon atoms in the alkyl group, 
and pharmaceutically usable hydrates, acid addition salts and alkali 
metal, alkaline earth metal, silver and guanidinium salts thereof, and in 
the form of their esters and in the other customary prodrug forms, have a 
powerful antibacterial action. 
They are therefore suitable as active compounds for human medicine and 
veterinary medicine, veterinary medicine also including the treatment of 
fish for therapy or prevention of bacterial infections. 
Preferred compounds of the formula (I) are those 
in which 
X represents chlorine or fluorine and 
A represents 
##STR6## 
or halogen, in particular chlorine or fluorine, 
wherein 
R.sup.1 represents hydrogen, a branched or straight-chain alkyl group with 
1 to 3 carbon atoms, which can optionally be substituted by a hydroxyl 
group, or a phenacyl radical which is optionally substituted by chlorine 
or fluorine, an oxoalkyl radical with 3 or 4 carbon atoms, 4-aminobenzyl, 
formyl or acetyl, 
R.sup.2 represents hydrogen or methyl, or phenyl which is optionally 
substituted by chlorine or fluorine, 
R.sup.3 represents hydrogen or methyl and 
R.sup.4 represents hydrogen, hydroxyl, amino, aminomethyl, 
methylaminomethyl, ethylaminomethyl or diethylaminomethyl. 
Particularly preferred compounds of the formula (I) are those 
in which 
X represents chlorine or fluorine and 
A represents 
##STR7## 
or halogen, in particular chlorine or fluorine, 
wherein 
R.sup.1 represents hydrogen, methyl, ethyl, 2-hydroxyethyl, phenacyl, 
2-oxopropyl, 3-oxobutyl or formyl, 
R.sup.2 represents hydrogen, methyl or phenyl, 
R.sup.3 represents hydrogen or methyl and 
R.sup.4 represents hydrogen, amino, aminomethyl, ethylaminomethyl or 
diethylaminomethyl. 
The compounds of the formula (I) in the form of their methyl, ethyl, 
pivaloyloxymethyl, pivaloyloxyethyl or 
(5-methyl-2-oxo-1,3-dioxol-4-yl-methyl) esters are moreover preferred. 
It has furthermore been found that the compounds of the formula (I) are 
obtained by a process in which the 
1-cyclopropyl-7-halogeno-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic 
acids of the formula (II) 
##STR8## 
in which X has the abovementioned meaning and 
Y represents halogen, preferably chlorine or fluorine, are reacted with 
amines of the formula (III) 
EQU A--H 
in which 
A has the abovementioned meaning, if appropriate in the presence of 
acid-binding agents (method A). 
Compounds of the formula (I) according to the invention can also be 
obtained by a process in which 
1-cyclopropyl-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carb 
oxylic acids of the formula (IV) 
##STR9## 
in which X, R.sup.2 and R.sup.3 have the abovementioned meaning, are 
reacted with compounds of the formula (V) 
EQU R.sup.1 --Z (V) 
in which 
R.sup.1 has the abovementioned meaning, but cannot be hydrogen, and 
Z denotes halogen, in particular chlorine, bromine or iodine, acyloxy, 
ethoxy or hydroxyl, if appropriate in the presence of acid-binding agents 
(method B). 
Compounds of the formula (I) (R.sup.1 =CH.sub.3 --CO--CH.sub.2 CH.sub.2 --) 
according to the invention are also obtained by a process in which a 
compound of the formula (IV) is reacted with methyl vinyl ketone of the 
formula (VI) 
EQU CH.sub.3 --CO--CH=CH.sub.2 (VI) 
(method C). 
If 2-methylpiperazine and 
7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carb 
oxylic acid are used as starting substances in the reaction according to 
method A, the course of the reaction can be represented by the following 
equation: 
##STR10## 
If, for example, chloroacetone and 
6-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridi 
ne-3-carboxylic acid are used as starting substances in the reaction 
according to method B, the course of the reaction can be represented by 
the following equation: 
##STR11## 
If, for example, methyl vinyl ketone and 
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridi 
ne-3-carboxylic acid are used as starting compounds according to method C, 
the course of the reaction can be represented by the following equation: 
##STR12## 
The 
1-cyclopropyl-7-halogeno-1,4-dihydro-4-oxo-1,8-naphthridine-3-carboxylic a 
cids of the formula (II) used as starting substances according to method A 
can be prepared in accordance with the following equation: 
##STR13## 
According to this reaction, diethyl malonate (2) is acylated with the 
corresponding nicotinic acid halide (1) 
in the presence of magnesium ethylate to give the acylmalonate (3) 
(Organicum, 3rd edition 1964, page 438). 
Partial hydrolysis and decarboxylation of (3) in an aqueous medium with 
catalytic amounts of sulfuric acid or 4-toluenesulfonic acid gives a good 
yield of the ethyl acylacetate (4), which is converted into the ethyl 
2-(nicotinoyl)-3-ethoxy-acrylate (5) with triethyl orthoformate/acetic 
anhydride. Reaction of (5) with cyclopropylamine in a solvent, such as, 
for example, methylene chloride, an alcohol, chloroform, cyclohexane or 
toluene, leads to the desired intermediate product (6) in a slightly 
exothermic reaction. 
The cyclization reaction (6).fwdarw.(7) is carried out in a temperature 
range of about 60.degree. to 300.degree. C., preferably 80.degree. to 
180.degree. C. 
Diluents which can be used are dioxane, dimethylsulfoxide, 
N-methylpyrrolidone, sulfolane, hexamethylphosphoric acid trisamide and, 
preferably, N,N-dimethylformamide. 
Possible acid-binding agents for this reaction stage are potassium 
tert.-butanolate, butyl-lithium, lithiumphenyl, phenyl-magnesium bromide, 
sodium methylate, sodium hydride and sodium or potassium carbonate. 
Potassium fluoride or sodium fluoride are particularly preferred if 
hydrogen fluoride has to be split off. It may be advantageous to employ an 
excess of 10 mol % of base. 
The ester hydrolysis of (7) under basic or acid conditions carried out in 
the last step leads to the 
1-cyclopropyl-7-halogeno-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic 
acids (II). 
The 2,5,6-trichloropyridine-3-carboxylic acid chloride [Helv. Chim. Acta 
59, 222 (1976)] used as the starting substance for this synthesis route is 
already known. 2,6-Dichloro-5-fluoro-pyridine-3-carboxylic acid chloride 
can be obtained by the following route: 
5-amino-2,6-dichloro-3-methylpyridine [Helv. Chim. Acta 59, 190 (1976)] 
is converted into 2,6-dichloro-5-fluoro-3-methylpyridine via 
2,6-dichloro-3-methyl-5-(3,3-dimethyl-1-triazeno)-pyridine or by a 
Baltz-Schiemann reaction. This product is chlorinated to give 
2,6-dichloro-5-fluoro-3-trichloromethyl-pyridine. Subsequent hydrolysis 
with sulfuric acid gives the carboxylic acid, which is converted into 
2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid chloride by the customary 
route. Alternatively, it is also possible to convert 
5-fluoro-2,6-dihydroxy-pyridine-3-carboxamide [J. Amer. Chem. Soc. 101, 
4423 (1979); J. Org. Chem. 46, 846 (1981)] into 
2,6-dichloro-5-fluoro-pyridine-3-carbonitrile with phosphorus oxychloride 
and likewise to convert this product into the acid chloride, after 
hydrolysis to the carboxylic acid. Oxidation of 
2,6-dichloro-3-chloromethyl-5-nitro-pyridine [Helv. Chim. Acta 59, 190 
(1976)] gives the corresponding nicotinic acid, which gives 
2,6-dichloro-5-nitro-pyridine-3-carboxylic acid chloride with thionyl 
chloride. 
The amines of the formula (III) used as starting substances are known [U.S. 
No. 4,166,180 and J. Med. Chem. 26, 1116 (1983)]. Examples which may be 
mentioned are: piperazine, N-methylpiperazine, N-ethylpiperazine, 
N-(2-hydroxyethyl)-piperazine, N-(2-methoxyethyl)-piperazine, 
N-propylpiperazine, N-isopropylpiperazine, N-buytylpiperazine, 
N-(sec.-butyl)-piperazine, N-formylpiperazine, 2-methylpiperazine, cis- 
and trans-2,6-dimethylpiperazine, 2-phenylpiperazine, 
2-(4-fluorophenyl)-piperazine, 2-(4-chlorophenyl)-piperazine, 
2-(4-methylphenyl)-piperazine, 2-(4-methoxyphenyl)-piperazine, 
2-(4-hydroxyphenyl)-piperazine, 2-(2-thienyl)-piperazine, pyrrolidine, 
3-amino-pyrrolidine, 3-aminomethyl-pyrrolidine, 
3-methylaminomethyl-pyrrolidine, 3-dimethylaminomethyl-pyrrolidine, 
3-ethylaminomethyl-pyrrolidine and 3-hydroxy-pyrrolidine. 
The compounds of the formula (V) used as starting substances are known. 
Examples which may be mentioned are: methyl iodide, methyl bromide, ethyl 
iodide, ethyl bromide, 2-hydroxyethyl chloride, 3-hydroxypropyl chloride, 
n-propyl bromide, isopropyl iodide, n-butyl bromide, sec.-butyl iodide, 
isobutyl bromide, formic acid/acetic acid anhydride, ethyl formate, formic 
acid, acetic anhydride and acetyl chloride. 
The reaction of (II) with (III) according to method A is preferably carried 
out in a diluent, such as dimethylsulfoxide, N,N-dimethylformamide, 
hexamethyl-phosphoric acid trisamide, sulfolane, water, an alcohol, such 
as methanol, ethanol, n-propanol, isopropanol or glycol monomethyl ether, 
or pyridine. Mixtures of these diluents can also be used. 
Acid-binding agents which can be used are all the customary inorganic and 
organic acid-binding agents. These include, preferably, the alkali metal 
hydroxides, alkali metal carbonates, organic amines and amidines. 
Acid-binding agents which may be specifically mentioned as being suitable 
are: triethylamine, 1,4-diaza-bicyclo[2,2,2]-octane (DABCO), 
1,8-diaza-bicyclo[5,4,0]-undec-7-ene (DBU) or excess amine (III). 
The reaction temperatures can be varied within a substancial range. In 
general, the reaction is carried out between about 20.degree. and 
200.degree.C., preferably between 80.degree. and 180.degree.C. 
The reaction can be carried out under normal pressure or under increased 
pressure. The reaction is in general carried out under pressures between 
about 1 and about 100 bar, preferably between 1 and 10 bar. 
In carrying out the process according to the invention, 1 to 15 moles, 
preferably 1 to 6 moles, of the amine (III) are employed per mole of the 
carboxylic acid (II). 
Free amino groups can be protected by a suitable amino-protective group, 
for example the t-butoxycarbonyl, ethoxycarbonyl or acetyl group, during 
the reaction, and liberated again after the reaction has ended. An 
aromatic amino group is introduced via reduction of a nitro group. 
The reaction of (IV) with (V) is preferably carried out in a diluent, such 
as dimethylsulfoxide, dioxane, N,N-dimethylformamide, 
hexamethyl-phosphoric acid trisamide, sulfolane, water, an alcohol, such 
as methanol, ethanol, n-propanol, isopropanol or glycol monomethyl ether, 
or pyridine. Mixtures of these diluents can also be used. 
Acid-binding agents which can be used are all the customary inorganic and 
organic acid-binding agents. These include, preferably, the alkali metal 
hydroxides, alkali metal carbonates, organic amines and amidines. 
Acid-binding agents which may be mentioned specifically as being 
particularly suitable are: triethylamine, 1,4-diazabicyclo[2,2,2]octane 
(DABCO) or 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU). 
The reaction temperatures can be varied within a substantial range. In 
general, the reaction is carried out between about 20.degree. and about 
180.degree.C., preferably between 40.degree. and 110.degree.C. 
The reaction can be carried out under normal pressure, but also under 
increased pressure. In general, the reaction is carried out under 
pressures between about 1 and about 100 bar, preferably between 1 and 10 
bar. 
In carrying out the process of method B according to the invention, 1 to 4 
moles, preferably 1 to 1.5 moles, of the compound (V) are employed per 
mole of the compound (IV). 
The reaction of (IV) with (VI) (method C) is preferably carried out in a 
diluent, such as dioxane, dimethylsulfoxide, N,N-dimethylformamide, 
methanol, ethanol, isopropanol, n-propanol or glycol monomethyl ether, or 
in mixtures of these diluents. 
The reaction temperatures can be varied within a substantial range. In 
general, the reaction is carried out between about 20.degree.C. and about 
150.degree.C., preferably between 50.degree.C. and 100.degree.C. 
The reaction can be carried out under normal pressure, but also under 
increased pressure. In general, the reaction is carried out under 
pressures between about 1 and about 100 bar, preferably between 1 and 10 
bar. 
In carrying out the process of method C according to the invention, 1 to 5 
moles, preferably 1 to 2 moles, of the compound (VI) are employed per mole 
of the compound (IV). 
The acid addition salts of the compounds according to the invention are 
prepared in the customary manner, for example by dissolving the betaine in 
excess aqueous acid and precipitating the salt with a water-miscible 
organic solvent (methanol, ethanol, acetone or acetonitrile). It is also 
possible to heat equivalent amounts of betaine and acid in water until a 
solution is obtained and then to evaporate the solution to dryness. 
Pharmaceutically usable salts are to be understood as, for example, the 
salts of hydrochloric acid, sulfuric acid, acetic acid, glycolic acid, 
lactic acid, succinic acid, citric acid, tartaric acid, methanesulfonic 
acid, galacturonic acid, gluconic acid, glutamic acid and asparaginic 
acid. 
The alkali metal or alkaline earth metal salts are obtained, for example, 
by dissolving the betaine in less then the stoichiometric amount of alkali 
metal or alkaline earth metal hydroxide solution, filtering off the 
undissolved betaine and evaporating the filtrate to dryness. Sodium, 
potassium or calcium salts are pharmaceutically suitable. the 
corresponding silver salts of the 
1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxy-lic acids are obtained by 
reacting an alkali metal salt or alkaline earth metal salt with a suitable 
silver salt, such as silver nitrate. 
New active compounds which may be mentioned specifically, in addition to 
the compounds listed in the examples, are: 
1-cyclopropyl-6-fluoro-1,4-dihydro-7-(3,5-dimethyl-1-piperazinyl)-4-oxo-1, 
8-naphthyridine-3-carboxylic acid, 
1-cyclopropyl-6-fluoro-1,4-dihydro-7-(4-isopropyl-1-piperazinyl)-4-oxo-1,8 
-naphthyridine-3-carboxylic acid, 
7-(4-butyl-1-piperazinyl)-6-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-nap 
hthyridine-3-carboxylic acid, 
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-phenacyl-1-piperazinyl)-1,8- 
naphthyridine-3-carboxylic acid, 
1-cyclopropyl-6-fluoro-1,4-dihydro-7-(3,4-dimethyl-1-piperazinyl)-4-oxo-1, 
8-naphthyridine-3-carboxylic acid hydrochloride, 
1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-methyl-4-(2-oxopropyl)-1-piperazin 
yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid, 
6-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-7-[4-(3-oxobutyl)-1-piperazinyl]- 
1,8-naphthyridine-3-carboxylic acid, 
1-cyclopropyl-6-fluoro-7-(4-formyl-1-piperazinyl)-1,4-dihydro-4-oxo-1,8-na 
phthyridine-3-carboxylic acid, 
7-(4-acetyl-1-piperazinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-na 
phthyridine-3-carboxylic acid, 
6-chloro-1-cyclopropyl-1,4-dihydro-7-(1-piperazinyl)-4-oxo-1,8-naphthyridi 
ne-3-carboxylic acid, 
6-chloro-1-cyclopropyl-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-1,8-na 
phthyridine-3-carboxylic acid, 
6-chloro-1-cyclopropyl-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-1,8-na 
phthyridine-3-carboxylic acid, 
6-chloro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-1,4-dihydro-4-oxo-1,8-nap 
hthyridine-3-carboxylic acid, 6-chloro-1-cyclopropyl-1,4-dihydro-4 
-oxo-7-[4-(3-oxopropyl)-1-piperazinyl]-1,8 -naphthyridine-3-carboxylic 
acid hydrochloride, 
1-cyclopropyl-6-fluoro-7-[3-(4-fluorophenyl)-1-piperazinyl]-1,4-dihydro-4- 
oxo-1,8-naphthyridine-3-carboxylic acid, 
6-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-7-(3-phenyl-1-piperazinyl)-1,8-na 
phthyridine-3-carboxylic acid, 
1-cyclopropyl-1,4-dihydro-6-nitro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridin 
e-3-carboxylic acid, 
1-cyclopropyl-1,4-dihydro-7-(4-methyl-1-piperazinyl)-6-nitro-4-oxo-1,8-nap 
hthyridine-3-carboxylic acid, 
7-[4-(4-aminobenzyl)-1-piperazinyl]-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-na 
phthyridine-3-carboxylic acid, 
7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridi 
ne-3-carboxylic acid and 
1-cyclopropyl-7-(3-ethylaminomethyl-1-pyrrolidinyl)-1,4-dihydro-4-oxo-1,8- 
naphthyridine-3-carboxylic acid. 
This invention furthermore relates to compounds of the formula (VII) 
##STR14## 
in which X represents halogen or nitro, 
X' and X" are identical or different and represent halogen, in particular 
chlorine or fluorine, and 
R denotes OH, halogen, in particular chlorine, or alkoxycarbonylmethyl, 
with methyl or ethyl in the alkoxy part.

The following examples illustrate the invention: 
Preparation of the starting compounds 
EXAMPLE A 
2,6-Dichloro-3-methyl-5-(3,3-dimethyl-1-triazeno)-pyridine 
##STR15## 
285 ml of half-concentrated hydrochloric acid are slowly added to 43 g 
(0.24 mole) of 5-amino-2,6-dichloro-3-methyl-pyridine (Helv. Chim. Acta 
59, 190 [1976]), the mixture is cooled to 0.degree., a solution of 17.2 g 
(0.25 mole) of sodium nitrite in 70 ml of water is added dropwise and the 
mixture is subsequently stirred at 0.degree. for some time. This diazonium 
salt solution is added dropwise to a solution of 150 g of sodium carbonate 
in 430 ml of water and 70 ml of 40-50% strength aqueous dimethylamine 
solution at 0.degree.-3.degree. in the course of 90 minutes and the 
mixture is subsequently stirred at 0.degree.. The precipitate is filtered 
off with suction, rinsed thoroughly with water and dried under a high 
vacuum at 40.degree. C. 
Yield: 49.3 g (88% of theory), melting point: 91.degree.-95.degree. C. 
EXAMPLE B 
2,6-Dichloro-5-fluoro-3-methyl-pyridine 
##STR16## 
43.9 g (0.19 mole) of 
2,6-dichloro-3-methyl-5-(3,3-dimethyl-1-triazeno)-pyridine are decomposed 
in 80 ml of hydrofluoric acid at 125.degree.-135.degree. C. in an 
autoclave. After distillation-, a product is obtained which has a purity, 
determined by gas chromatography, of 87% and in addition also contains 12% 
of chlorine/fluorine replacement product. Yield: 19 g, boiling point: 
81.degree.-95.degree./18 mbar Melting point: 39.degree.-41.degree. C. 
EXAMPLE C 
2,6-Dichloro-5-fluoro-3-trichloromethyl-pyridine 
##STR17## 
49.4 g (0.27 moles) of 2,6-dichloro-5-fluoro-3-methyl-pyridine are 
chlorinated at 120.degree. C. for a total of about 20 hours, until the 
aliphatic proton is no longer detectable by NMR spectroscopy. The reaction 
mixture is distilled in a bulb tube distillation apparatus. 
Yield: 61.7 g (80.6%), boiling point: 130.degree.-150.degree. C. (oven 
temperature)/0.4 mbar. 
Mass spectrum: m/e 281 (M.sup.+), 246 (100%, M.sup.+ --Cl), 211 (246-Cl) 
and 176 (211-Cl). 
EXAMPLE D 
2,6-Dichloro-5-fluoro-pyridine-3-carboxylic acid 
##STR18## 
57 g (0.2 mole) of 2,6-dichloro-5-fluoro-3-trichloromethyl-pyridine are 
dissolved in 53 ml of 92% strength sulphuric acid and the mixture is 
stirred first at 25.degree. C. for 45 minutes and then at 100.degree. C. 
for 3 hours, until the evolution of hydrogen chloride has subsided. 24 g 
of 50% strength sulfuric acid are added and the mixture is heated at 
100.degree. C. for a further 6 hours. The reaction mixture is then cooled 
and poured onto ice and the precipitate is filtered off with suction, 
washed with water and dried. 
Crude yield: 42 g (.about.100% of theory), melting point: 
137.degree.-149.degree. C.; after recrystallisation from water: melting 
point: 154.degree.-161.degree. C. 
Mass spectrum: m/e 209 (M.sup.+), 192 (M.sup.+ --OH), 164 (192-CO), 129 
(164-Cl) and 94 (129-Cl). 
EXAMPLE E 
2,6-Dichloro-5-fluoro-pyridine-3-carbonyl chloride 
##STR19## 
42 g (0.2 mole) of 2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid are 
heated under reflux in a mixture of 43 g of thionyl chloride. 15 ml of 
dimethylformamide and 640 ml of toluene for 6 hours. The mixture is 
concentrated and the residue is distilled. 
Yield: 33.8 g (74% of theory), boiling point 94.degree.-98.degree. C./1.3 
mbar. 
Mass spectrum: m/e 227 (M.sup.+), 192 (100%, M.sup.+ --Cl) and 164 (40%, 
M.sup.+ --COCl). 
EXAMPLE F 
Ethyl (2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-acetate 
##STR20## 
0.8 g of carbon tetrachloride is added to 3.7 g (0.15 mole) of magnesium 
filings in 9.3 ml of ethanol and, when the evolution of hydrogen has 
started, a mixture of 23.9 g (0.15 mole) of diethyl malonate, 18.5 ml of 
ethanol and 58 ml of toluene is added dropwise at 50.degree.-60.degree. C. 
The mixture is subsequently stirred at this temperature for 1 hour and 
cooled to -5.degree. to -10.degree. C. and a solution of 31 g (0.14 mole) 
of 2,6-dichloro-5-fluoro-pyridine-3-carbonyl chloride in 14.5 ml of 
toluene is slowly added dropwise. Thereafter, the mixture is stirred at 
0.degree. for 1 hour, brought to room temperature overnight and warmed at 
40.degree.-50.degree. C. for a further 2 hours. A mixture of 60 ml of 
water and 9 ml of concentrated sulfuric acid is added to the reaction 
mixture, while cooling with ice, and the organic phase is separated off. 
The aqueous phase is extracted with toluene, the combined organic extract 
is washed with saturated sodium chloride solution and dried with sodium 
sulphate and the solvent is stripped off. 50.1 g of diethyl 
(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-malonate are obtained as a 
crude product. This product is heated under reflux for 10 hours, after 
addition of 50 ml of water and 0.1 g of 4-toluenesulfonic acid, the 
mixture is extracted with methylene chloride, the extract is dried with 
sodium sulphate and concentrated, the residue is stirred with a little 
ether and the crystals are isolated. 
Yield: 14.3 g (34% of theory), melting point: 69.degree.-72.degree. C. 
Mass spectrum: m/e 279 (M.sup.+), 244 (60%, M.sup.+ --Cl), 216 (74%, 
244-28), 192 (100%, C.sub.6 HCl.sub.2 FNO), 164 and 29. 
According to the NMR spectrum (CDCl.sub.3), the compound is present 
virtually entirely as the enol. 
EXAMPLE G 
7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carbo 
xylic acid 
##STR21## 
14 g (50 mmol) of ethyl (2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-acetate 
are heated at 150.degree.-160.degree. C. with 11.1 g (75 mmol) of triethyl 
orthoformate in 13 g of acetic anhydride for 2 hours. The mixture is 
concentrated in vacuo and 15.6 g of ethyl 
2-(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-3-ethoxyacrylate are 
obtained as an oily residue. 
3 g of cyclopropylamine are added dropwise to 15.5 g (46 mmol) of this 
intermediate stage in 35 ml of ethanol, while cooling with ice, and the 
mixture is stirred at 20.degree. C. for 1 hour. The product which has 
precipitated is filtered off with suction, washed with methanol and dried. 
13.3 g of ethyl 
2-(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-3-cyclopropylaminoacrylate 
of melting point 130.degree.-133.degree. C. (from ethanol) are obtained. 
12.5 g (36 mmol) of ethyl 
2-(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)-3-cyclopropylamino-acrylate 
are heated at 100.degree. C. in 75 ml of dimethylformamide with 6.5 g of 
potassium carbonate for 1 hour. The reaction mixture is poured onto 
ice-water and the product which has precipitated is filtered off with 
suction, washed with water and methanol and dried. 10.5 g (94% of theory) 
of ethyl 
7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carb 
oxylate of melting point 176.degree.-180.degree. C. are obtained. 
10.5 g (34 mmol) of this ester are heated at 150.degree. C. in a mixture of 
100 ml of acetic acid, 70 ml of water and 10 ml of concentrated sulfuric 
acid for 2 hours. The suspension is poured into 300 ml of ice-water and 
the precipitate is filtered off with suction, washed with water and 
methanol and dried in vacuo. 
Yield: 7.85 g (82% of theory) of 
7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carb 
oxylic acid of melting point 230.degree.-233.degree. C. 
EXAMPLE H 
6,7-Dichloro-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic 
acid 
##STR22## 
Ethyl (2,5,6-trichloropyridine-3-carbonyl)-acetate (melting point: 
69.degree.-71.degree.; according to the .sup.1 H-NMR spectrum in 
denterochloroform, present as the enol to the extent of 50%) is prepared 
analogously to Example F starting from 
2,5,6-trichloropyridine-3-carboxylic acid chloride [Helv. Chim. Acta 59, 
222 (1976)]. This product is then converted analogously to Example G, via 
ethyl 
6,7-dichloro-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxyla 
te (melting point: 176.degree.-178.degree.), into 
6,7-dichloro-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxyli 
c acid, which, after recrystallisation from dimethylformamide, has a 
melting point of 243.degree.-245.degree., with decomposition. 
EXAMPLE 1 
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridin 
e-3-carboxylic acid 
##STR23## 
1.3 g (4 mmol) of 
7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carb 
oxylic acid are heated at 110.degree. C. in 8 ml of dimethylsulfoxide with 
860 mg (10 mmol) of anhydrous piperazine for 15 minutes. The solvent is 
evaporated off in vacuo, the residue is boiled up with 5 ml of water (pH 
7) and the precipitate is filtered off with suction, washed with water and 
boiled up with methanol. 
Yield: 1.0 g (75% of theory), melting point: 278.degree.-282.degree. C. 
(with decomposition). 
EXAMPLE 2 
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-1,8-nap 
hthyridine-3-carboxlyic acid 
##STR24## 
The procedure is analogous to Example 1, the reaction being carried out 
with 2-methylpiperazine at 100.degree. C. for 15 minutes and the reaction 
product being recrystallised from glycol monomethyl ether. 
Yield: 0.9 g (65% of theory), melting point: 243.degree.-247.degree. C. 
(with decomposition). 
EXAMPLE 3 
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-1,8-nap 
hthyridine-3-carboxylic acid hydrochloride 
##STR25## 
The procedure is analogous to Example 1, the reaction being carried out 
with N-methylpiperazine at 100.degree. C. for 15 mintues and the reaction 
product being recrystallised from glycol monomethyl ether. The 
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-1,8-na 
phthyridine-3-carboxylic acid obtained (1.2 g of melting point 
241.degree.-244.degree. C., with decomposition) is boiled up in a mixture 
of 20 ml of ethanol and 5 ml of 2N hydrochloric acid, and the 
hydrochloride formed is filtered off with suction, washed with ethanol and 
dried. 
Yield: 1.1 g (72%), melting point: 305.degree.-310.degree. C. (with 
decomposition). 
EXAMPLE 4 
1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naph 
thyridine-3-carboxylic acid hydrochloride 
##STR26## 
The reaction is carried out analogously to Example 3 with 
N-ethyl-piperazine at 100.degree. C. for 30 minutes and the reaction 
product is then converted into the hydrochloride. Yield: 1.05 g (66% of 
theory), melting point: &gt;300.degree. C. (with decomposition). 
EXAMPLE 5 
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[4-(2-hydroxyethyl)-1-piperazinyl]-4-o 
xo-1,8-naphthyridine-3-carboxylic acid 
##STR27## 
The reaction is carried out analogously to Example 1 with 
N-(2-hydroxyethyl)-piperazine at 100.degree. C. for 30 minutes and the 
reaction product is recrystallised from glycol monomethyl ether. 
Yield: 0.9 g (60% of theory), melting point: 241.degree.-245.degree. C. 
(with decomposition). 
EXAMPLE 6 
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-phenyl-1-piperazinyl)-1,8-nap 
hthyridine-3-carboxylic acid 
##STR28## 
Analogously to Example 1, 810 mg (5 mmol) of 2-phenyl-piperazine are 
reacted in the presence of 1.8 g (8 mmol) of 
1,4-diaza-bicyclo[2,2,2]octane (DABCO) at 100.degree. C. for 30 minutes. 
Yield: 0.85 g (42% of theory), melting point: 280.degree.-283.degree. C. 
(with decomposition). 
EXAMPLE 7 
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pyrrolidinyl)-1,8-naphthyridi 
ne-3-carboxylic acid 
##STR29## 
Analogously to Example 1, pyrrolidine is reacted at 100.degree. C. for 30 
minutes and the reaction product is recrystallised from dimethylformamide. 
Yield: 70% of theory, melting point: 314.degree.-316.degree. C. (with 
decomposition). 
EXAMPLE 8 
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(2-oxopropyl)-1-piperazinyl]- 
1,8-naphthyridine-3-carboxylic acid hydrochloride 
##STR30## 
0.7 g (7.6 mmol) of chloroacetone and 1.05 g of triethylamine are added to 
1.65 g (5 mmol) of 
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridi 
ne-3-carboxylic acid in 25 ml of dimethylformamide and the mixture is 
heated at 80.degree. C. for 3 hours. The suspension is concentrated in 
vacuo and the residue is stirred with 10 ml of water, filtered off with 
suction and dried. The product is heated in 15 ml of dilute hydrochloric 
acid (1:1), precipitated with ethanol, filtered off with suction and 
dried. 
Yield: 1.5 g (71% of theory), melting point: &gt;300.degree. C. (with 
decomposition). 
EXAMPLE 9 
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[4-(3-oxobutyl)-1-piperazinyl]-1 
,8-naphthyridine-3-carboxylic acid hydrochloride 
##STR31## 
1.66 g (5 mmol) of the compound from Example 1 and 1.95 g (28 mmol) of 
methyl vinyl ketone are heated under reflux in 25 ml of ethanol for 7 
hours, the precipitate obtained is dissolved in dilute hydrochloric acid 
(1:1) and the product is precipitated with ethanol. 
Yield: 1.1 g (55% of theory), melting point: &gt;300.degree. C. (with 
decomposition). 
EXAMPLE 10 
6-Chloro-1-cyclopropyl-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-1,8-nap 
hthyridine-3-carboxylic acid hydrochloride 
##STR32## 
The procedure is analogous to Example 3, 
6,7-dichloro-1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxyli 
c acid and N-methyl-piperazine being used as starting compounds. 
Yield: 66%, melting point: 304.degree.-308.degree. (with decomposition). 
Examples of a tablet according to the invention 
______________________________________ 
Each tablet contains: 
Compound of Example 1 583.0 mg 
Microcrystalline cellulose 
55.0 mg 
Maize starch 72.0 mg 
Insoluble poly-(1-vinyl-2-pyrrolidone) 
30.0 mg 
Highly disperse silicon dioxide 
5.0 mg 
Magnesium stearate 5.0 mg 
750.0 mg 
The lacquer shell contains: 
Poly-(O--hydroxypropyl-O--methyl)- 
6.0 mg 
cellulose 15 cp 
Macrogol 4000 rec. INN 2.0 mg 
(polyethylene glycols DAB) 
Titanium(IV) oxide 2.0 mg 
10.0 mg 
______________________________________ 
The compounds according to the invention exhibit a broad antibacterial 
spectrum against Gram-positive and Gram-negative bacteria, in particular 
against Enterobacteriaceae, coupled with a low toxicity; in particular, 
they exhibit an action against those bacteria which are resistant towards 
various antibiotics, such as, for example, penicillins, cephalosporins, 
aminoglycosides, sulphonamides and tetracyclines. 
These useful properties enable them to be used as chemotherapeutic active 
compounds in medicine and as substances for preserving inorganic and 
organic materials, in particular all types of organic materials, for 
example polymers, lubricants, paints, fibres, leather, paper and wood, and 
foodstuffs and water. 
The compounds according to the invention are active against a broad 
spectrum of microorganisms. With their aid, it is possible to combat 
Gram-negative and Gram-positive bacteria and bacteria-like microorganisms, 
and the diseases caused by these pathogens can be prevented, alleviated 
and/or cured. 
The compounds according to the invention are particularly active against 
bacteria and bacteria-like microorganisms. They are therefore particularly 
suitable, in human medicine and veterinary medicine, for the prophylaxis 
and chemotherapy of local and systemic infections caused by these 
pathogens. 
For example, local and/or systemic diseases which are caused by the 
following pathogens or by mixtures of the following pathogens can be 
treated and/or prevented: Gram-positive cocci, for example Staphylococci 
(Staph. aureus and Staph. epidermidis) and Streptococci (Strept. 
agalactiae, Strept. faecalis, Strept. pneumoniae and Strept. pyogenes); 
Gram-negative cocci (Neisseria gonorrhoeae) and Gram-negative rod-shaped 
bacillae, such as Enterobacteriaceae, for example Escherichia coli, 
Haemophilius influenzae, Citro-bacter (Citrob. freundii and Citrob. 
divernis), Salmonella and Shigella; and furthermore Klebsiellae (Klebs. 
pneumoniae and Klebs. oxytoca), Enterobacter (Ent. aerogenes and Ent. 
agglomerans), Hafnia, Serratia (Serr. marcescens), Proteus (Pr. mirabilis, 
Pr. rettgeri and Pr. vulgaris), Providencia, Yersinia and the genus 
Acinetobacter. The antibacterial spectrum moreover includes the genus 
Pseudomonas (Ps. aeruginosa and Ps. maltophilia) and strictly anaerobic 
bacteria, such as, for example, Bacteroides fragilis, representatives of 
the genus Peptococcus, Peptostreptococcus and the genus Clostridium, and 
furthermore Mykoplasma (M. pneumoniae, M. hominis and M. urealyticum) and 
Mycobacteria, for example Mycobacterium tuberculosis. 
The above list of pathogens is purely illustrative and is no way to be 
interpreted as restrictive. Examples which may be mentioned of diseases 
which can be prevented, alleviated and/or cured by the compounds according 
to the invention are: otitis; pharyngitis; pneumonia; peritonitis; 
pyelonephritis; cystitis; endocarditis; systemic infections; bronchitis; 
arthritis; local infections; and septic diseases. 
The present invention includes pharmaceutical formulations which, in 
addition to non-toxic, inert pharmaceutically suitable excipients, contain 
one or more compounds according to the invention, or which consist of one 
or more compounds according to the invention, as well as processes for the 
preparation of these formulations. 
The present invention also includes pharmaceutical formulations in dosage 
units. This means that the formulations are in the form of individual 
parts, for example tablets, dragees, capsules, pills, suppositories and 
ampoules, of which the active compound content corresponds to a fraction 
or a multiple of an individual dose. The dosage units can contain, for 
example, 1, 2, 3 or 4 individual doses or 1/2, 1/3 or 1/4 of an individual 
dose. An individual dose preferably contains the amount of active compound 
which is given in one administration and which usually corresponds to a 
whole, a half, a third or a quarter of a daily dose. 
By non-toxic, inert pharmaceutically suitable excipients there are to be 
understood solid, semi-solid or liquid diluents, fillers and formulation 
auxiliaries of every kind. 
Tablets, dragees, capsules, pills, granules, suppositories, solutions, 
suspensions and emulsions, pastes, ointments, gels, creams, lotions, 
powders and sprays may be mentioned as preferred pharmaceutical 
formulations. 
Tablets, dragees, capsules, pills and granules can contain the active 
compound or compounds alongside the customary excipients, such as (a) 
fillers and extenders, for example starches, lactose, sucrose, glucose, 
mannitol and silica, (b) binders, for example carboxymethylcellulose, 
alginates, gelatine and polyvinylpyrrolidone, (c) humectants for example 
glycerol, (d) disintegrating agents, for example agar-agar, calcium 
carbonate and sodium carbonate, (e) solution retarders, for example 
paraffin and (f) absorption acceclerators, for example quaternary ammonium 
compounds (g) wetting agents, for example cetyl alcohol and glycerol 
monostearate, (h) adsorbents, for example kaolin and bentonite, and (i) 
lubricants, for example talc, calcium stearate, magnesium stearate and 
solid polyethylene glycols, or mixtures of the substances listed under (a) 
to (i). 
The tablets, dragees, capsules, pills and granules can be provided with the 
customary coatings and shells, optionally containing opacifying agents, 
and can also be of such composition that they release the active compound 
or compounds only, or preferentially, in a certain part of the intestinal 
tract, optionally in a delayed manner, examples of embedding compositions 
which can be used being polymeric substances and waxes. 
The active compound or compounds, optionally together with one or more of 
the abovementioned excipients, can also be in microencapsulated form. 
Suppositories can contain, in addition to the active compound or compounds, 
the customary water-soluble or water-insoluble excipients, for example 
polyethylene glycols, fats, for example cocoa fat, and higher esters (for 
example C.sub.14 -alcohol with C.sub.16 -fatty acid), or mixtures of these 
substances. 
Ointments, pastes, creams and gels can contain, in addition to the active 
compound or compounds, the customary excipients, for example animal and 
vegetable fats, waxes, paraffins, starches, tragacanth, cellulose 
derivatives, polyethylene glycols, silicones, bentonites, silica, talc and 
zinc oxide, or mixtures of these substances. 
Powders and sprays can contain, in addition to the active compound or 
compounds, the customary excipients, for example lactose, talc, silica, 
aluminium hydroxide, calcium silicate and polyamide powder, or mixtures of 
these substances. Sprays can additionally contain the customary 
propellants, for example chlorofluorohydrocarbons. 
Solutions and emulsions can contain, in addition to the active compound or 
compounds, the customary excipients, such as solvents, solubilising agents 
and emulsifiers, for example water, ethyl alcohol, isopropyl alcohol, 
ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene 
glycol, 1,3-butylene glycol, dimethylformamide, oils, especially 
cottonseed oil, groundnut oil, maize germ oil, olive oil, castor oil and 
sesame oil, glycerol, glycerolformal, tetrahydrofurfuryl alcohol, 
polyethylene glycols and fatty acid esters of sorbitan, or mixtures of 
these substances. 
For parenteral administration, the solutions and emulsions can also be in a 
sterile form which is isotonic with blood. 
Suspensions can contain, in addition to the active compound or compounds, 
the customary excipients, such as liquid diluents, for example water, 
ethyl alcohol or propylene glycol, suspending agents, for example 
ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters and 
sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, 
bentonite, agar-agar and tragacanth, or mixtures of these substances. 
The formulation forms mentioned can also contain colorants, preservatives 
and additives which improve the odor and flavor, for example peppermint 
oil and eucalyptus oil, and sweeteners, for example saccharin. 
The therapeutically active compounds should preferably be present in the 
abovementioned pharmaceutical formulations in a concentration of about 0.1 
to 99.5, preferably of about 0.5 to 95% by weight of the total mixture. 
The abovementioned pharmaceutical formulations can also contain other 
pharmaceutical active compounds in addition to the compounds according to 
the invention. 
The abovementioned pharmaceutical formulations are prepared in the 
customary manner according to known methods, for example by mixing the 
active compound or compounds with the excipient or excipients. 
The active compounds or the pharmaceutical formulations can be administered 
locally, orally, parenterally, intraperitoneally and/or rectally, 
preferably orally or parenterally, such as intravenously or 
intramuscularly. 
In general, it has proven advantageous both in human medicine and in 
veterinary medicine to administer the active compound or compounds 
according to the invention in total amounts of about 0.5 to about 500, 
preferably 5 to 100 mg/kg of body weight every 24 hours, optionally in the 
form of several individual administrations, in order to achieve the 
desired results. An individual administration preferably contains the 
active compound or compounds according to the invention in amounts of 
about 1 to about 250, in particular 3 to 60 mg/kg of body weight. However, 
it may be necessary to deviate from the dosages mentioned, and in 
particular to do so as a function of the species and body weight of the 
subject to be treated, the nature and severity of the disease, the nature 
of the formation and of the administration of the medicament and the 
period of interval within which administration takes place. 
Thus it can in some cases suffice to manage with less than the 
abovementioned amount of active compound, whilst in other cases the 
abovementioned amount of active compound must be exceeded. The particular 
optimum dosage and mode of administration of the active compounds can 
easily be determined by anyone skilled in the art on the basis of his 
expert knowledge. 
The new compounds can be administered in the customary concentrations and 
formulations together with the feed or with feed formulations or with the 
drinking water. Infection by Gram-negative or Gram-positive bacteria can 
thereby be prevented, alleviated and/or cured, and a promotion in growth 
and an improvement in feed utilisation can thereby be achieved. 
The MIC values of some of the compounds according to the invention are 
given in the following table. 
As a comparison, the corresponding MIC values of 
1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-c 
arboxylic acid (AT 2266, enoxacin), which is known from European Patent 
Application 9,425, Japanese Patent Applications 81/45473 [C.A. 95, 115 597 
(1981)] and 81/46811 [C.A. 95, 121 142 (1981)], from J. Med. Chem. 27, 292 
(1984) or from J. Heterocycl. Chem. 21, 673 (1984), have been given, it 
being found that the compounds according to the invention are superior to 
the known compound. 
TABLE 1 
______________________________________ 
MIC values (mcg/ml) 
Exam- 
Strain Example 1 ple 2 Example 3 
Enoxacin 
______________________________________ 
E.coli 4418 0.03 0.03 0.06 0.25 
E.coli Neum. 
.ltoreq.0.015 
.ltoreq.0.015 
.ltoreq.0.015 
0.06 
E.Coli 455/7 
4 8 8 16 
Klebsiella 63 
0.03 .ltoreq.0.015 
.ltoreq.0.015 
0.5 
Klebsiella 6179 
0.125 0.125 0.03 2 
Proteus mir. 8175 
0.125 0.25 0.25 0.25 
Proteus vulg. 1017 
0.06 0.125 0.125 0.125 
Proteus morg. 11006 
0.06 0.03 0.06 0.125 
Providencia 12012 
0.03 0.125 0.06 0.25 
Serratia 16040 
8 8 8 32 
Staphyloc. 1756 
0.5 0.5 0.5 1 
Staphyloc. 133 
0.5 0.5 0.5 1 
Pseudomonas W. 
0.125 1 1 2 
______________________________________ 
Agar dilution test / Isosensitest medium